welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new data supporting magnetic resonance imaging (MRI) T2 as a potential marker of clinical outcome in boys with Duchenne Muscular Dystrophy (DMD). Data from ImagingDMD, the largest natural history database of MRI assessments in boys with DMD, demonstrate a strong correlation between a composite of lower leg MRI T2 and boys’ functional abilities. These results highlight the clinical importance of the significant improvement observed in the MoveDMD trial with edasalonexent treatment for lower leg MRI T2 compared to the off-treatment control period. These data were presented today in the late breaking session at the 23rd International Congress of the World Muscle Society in Mendoza, Argentina.
rareRelated
-
Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMDThis study will collect MRI from healthy...
-
Glenn A. Walter, PhDGlenn Walter is an Associate Professor i...
-
Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2IThe purpose of this study is to investig...
-
Cardiac MRI Biomarkers for Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a f...
-
Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy c...Objective: The aim of this study was to...
-
Upper arm, pulmonary and cardiac magnetic resonance imaging for relative disease status in Duchenne muscular dystrop...Objective: To simultaneously assess the...
-
Association between specific dystrophin gene mutations and myocardial fibrosis by cardiovascular magnetic resonance ...Background Duchenne (DMD) and Becker (B...
